罗氟司特哪里有卖？

Roflumilast is a second-generation highly selective PDE4 inhibitor. In 2011, the U.S. Food and Drug Administration (FDA) approved it for the treatment of chronic obstructive pulmonary disease (COPD), making it the first PDE4 inhibitor approved by the FDA. The treatment of COPD is related to its obvious anti-inflammatory effect by specifically inhibiting cAMP hydrolysis. In addition to its anti-inflammatory effect, there are also reports in the literature that it also has body weight reduction, anti-diabetic and anti-tumor effects. Its biggest advantage is that while it exerts its effect, it has relatively mild vomiting side effects.

In 2015, Jabaris et al. found that roflumilast could reverse the learning and memory dysfunction in hypertensive rats induced by the double-kidney clamp method. Since then, scientific workers have conducted extensive research on the role of roflumilast in cognitive function and found that it not only improves cognitive function in a variety of animal models, but clinical studies also found that it can improve the cognitive function of healthy volunteers and patients with schizophrenia, and its mechanism of action is mainly related to the cAMP, protein kinase A (PKA) and cAMP response element binding protein (CREB) signaling pathways.

FDA-approved dosing information for roflumilast shows potential mental health risks, including changes in mood, thinking, or behavior, and unexplained weight loss. Roflumilast is not expected to be used in the treatment of other symptoms of COPD, including emphysema. Roflumilast should not be used to treat sudden breathing problems (acute bronchospasm) and is not recommended for patients under 18 years of age. The main adverse reactions reported include: diarrhea, nausea, headache, insomnia, back pain, decreased appetite and dizziness.

It is not currently listed in China, so it is not eligible for medical insurance. In other words, if patients want to purchase the drug, they must go abroad to purchase it. Traveling abroad to buy medicines is a long journey and requires a lot of manpower and material resources. Coupled with the huge medical expenses, many patient families are overwhelmed. However, according to Medical Companion Travel, 500μg*90 tablets of roflumilast costs approximately $2,850 per box. Since the exchange rate has been in a state of fluctuation for a long time, the price fluctuates with the exchange rate and is not static. For more information about roflumilast, please contact Medical Companion Travel for details.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.